Fara Brasó-Maristany

About me

Featured publications

• Gene expression profiles of breast cancer metastasis according to organ site

  Authors:

  Brasó-Maristany, F; Chic, N; Martínez-Sáez, O; Mallafré-Larrosa, M; Schettini, F;

  (...)

  Pascual, T; Ciruelos, E; Salinas, B; Tolosa, P; Carcelero, E.

  See complete list of authors

  Reference: Molecular Oncology 2022.

• Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

  Authors:

  Braso-Maristany, F; Chic, N; Martinez, D; González-Farre, B; Sanfeliu, E;

  (...)

  Soy, D; Sanchez, M; Jares, P; Peg, V; Saura, C.

  See complete list of authors

  Reference: Frontiers In Oncology 2021.

• Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

  Authors:

  Chic, N; Schettini, F; Brasó-Maristany, F; Sanfeliu, E; Adamo, B;

  (...)

  Bellet, M; Cortés, J; Soberino, J; Carey, LA; Perou, CM.

  See complete list of authors

  Reference: Ebiomedicine 2021.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Authors:

  Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

  (...)

  Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

  See complete list of authors

  Reference: Journal Of Clinical Oncology 2021.

• Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

  Authors:

  Martínez-Sáez, O; Pascual, T; Brasó-Maristany, F; Chic, N; González-Farré, B;

  (...)

  Prat, A; Rodríguez, A; Martínez, A; Faull, I; Odegaard, JI.

  See complete list of authors

  Reference: Npj Breast Cancer 2021.

• A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

  Authors:

  Prat, Aleix; Tsai, Yi-Hsuan; Pascual, Tomas; Pare, Laia; Adamo, Barbara;

  (...)

  Brase, Jan Christoph; Rodrik-Outmezguine, Vanessa; Johnston, Stephen; Ciruelos, Eva; Parker, Joel S.

  See complete list of authors

  Reference: Clinical Cancer Research 2020.

• ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

  Authors:

  Griguolo, G; Giarratano, T; Dieci, MV; Conte, P; Guarneri, V;

  (...)

  Christgen, M; Kreipe, H; Monge-Escartín, I; Soy, D; Harbeck, N.

  See complete list of authors

  Reference: Cancers 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Authors:

  Brasó-Maristany, F; Griguolo, G; Pascual, T; Vidal, M; Adamo, B;

  (...)

  Manso, L; Alarcón, J; Martínez, E; Gregorio, S; Gomis, RR.

  See complete list of authors

  Reference: Nature Communications 2020.

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  Authors:

  Prat, A; Pascual, T; Paré, L; Adamo, B; Brasó-Maristany, F;

  (...)

  Parker, JS; Dieci, MV; Griguolo, G; Conte, P; Guarneri, V.

  See complete list of authors

  Reference: Journal Of The National Cancer Institute 2020.

• PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

  Authors:

  Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J;

  (...)

  Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN .

  See complete list of authors

  Reference: Nature Medicine 2016.

Featured Projects

• Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.

  Principal investigator: Fara Brasó Maristany

  Funder: Fundación Científica Asociación Española Contra el Cáncer (AECC).

  Code: INVES21943BRAS

  Duration: 01/12/2021 - 30/11/2024

• Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo

  Principal investigator: Aleix Prat

  Funder: Asociación Española Contra el Cáncer (AECC) ; Fundación Científica Asociación Española Contra el Cáncer (AECC).

  Code: Ayuda Postdoctoral AECC 2017

  Duration: 01/11/2017 - 31/10/2021

  Web: https://www.aecc.es/es/investigacion/proyectos-aecc/estudio-mecanismos-sensibilidad-resistencia-doble-bloqueo-her2-combinaciones-con-enzalutamida-o-palbociclib-modelos-preclinicos-cancer-mama-her2